Related Experiment Videos
[Hematopoietic stem cell transplantation for hematological malignancies]
Mei-zuo Zhong1, Fang-ping Chen, Yi-gang Shu
1Department of Hematology, Xiangya Hospital, Central South University, Changsha 410008, China.
Hunan Yi Ke Da Xue Xue Bao = Hunan Yike Daxue Xuebao = Bulletin of Hunan Medical University
|February 11, 2003
Summary
Hematopoietic stem cell transplantation (HSCT) shows efficacy in treating hematological malignancies. For acute leukemia patients, autologous HSCT combined with chemotherapy significantly reduces relapse rates.
Area of Science:
- Hematology
- Oncology
- Transplantation Medicine
Context:
- Hematological malignancies pose a significant clinical challenge.
- Hematopoietic stem cell transplantation (HSCT) is a crucial therapeutic modality.
- Evaluating HSCT efficacy in diverse hematological cancers is essential.
Purpose:
- To assess the effectiveness of various HSCT methods in treating hematological malignancies.
- To determine the impact of post-transplant chemotherapy on relapse rates in acute leukemia patients.
Summary:
- Twenty-five patients with hematological malignancies underwent autologous bone marrow transplantation (ABMT), autologous peripheral blood stem cell transplantation (APB-SCT), or allogeneic peripheral blood stem cell transplantation (Allo-PBSCT).
- Eight acute myeloid leukemia (AML) patients receiving autologous HSCT (AHSCT) also underwent subsequent chemotherapy.
- All patients achieved engraftment and hematopoietic reconstitution. Over a follow-up of 6-91 months, 20 patients remained disease-free, while five died.
Impact:
- HSCT demonstrates significant potential in managing hematological malignancies.
- Combining AHSCT with regular chemotherapy demonstrably lowers relapse incidence in acute leukemia.
- This study supports HSCT as a leading treatment option for hematological cancers.